Managing irAEs is a Dynamic Discussion
In this special edition podcast, we spoke with both a physician and a nurse about the management of immune-related adverse events in patients with melanoma.
In recent years, immunotherapy agents have shown amazing success in treating patients with melanoma. For this special-edition podcast, we teamed up with our sister publication, Oncology Live, to bring the viewpoints of 2 melanoma experts on the importance of multidisciplinary care when managing immune-related adverse events (irAEs).
You’ll hear from Grace Cherry, NP, of UCLA’s Melanoma Program, and Omid Hamid, MD, chief of research, immune-oncology and co-director of the cutaneous malignancy program at the Angeles Clinic and Research Institute. They discuss their team approach to handling irAEs, as well as offer tips on establishing an open line of patient and provider communication to ensure that toxicities are reported — and handled – in a timely manner.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
